Drug intelligence / Profile preview

LY3972406

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3972406 is an orally administered, small-molecule, highly selective Kv1.3 potassium channel inhibitor being developed for the treatment of moderate-to-severe plaque psoriasis and autoimmune diseases. It works by blocking the voltage-gated potassium channel subunit Kv1.3, which plays a role in immune system regulation. The drug was originally developed by D E Shaw Research and is currently being advanced by Eli Lilly and Company through clinical trials.

Targets

KCNA3 (Potassium voltage-gated channel subfamily A member 3)

Beyond the preview

Go deeper on LY3972406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3972406.

Explore the full profile